Abstract

IntroductionSelective internal radiotherapy (SIRT) with yttrium-90 (Y-90) is an intra-arterial therapy for hepatic malignancy in patients who are unsuitable for surgical resection. This treatment is considered palliative, although some patients can demonstrate a response that is adequate to facilitate surgical resection with curative intent.MethodsAll patients who underwent liver resection post SIRT were reviewed. Data gathered included patient demographics, tumor type, surgical details, and post-operative outcomes.ResultsTwelve patients underwent SIRT followed by liver resection (7 males and 5 females). Pathologies were hepatocellular carcinoma (n = 5), metastatic colorectal cancer (n = 5), and neuroendocrine tumor (n = 2). Lesional response (size, volume, and RECIST (response evaluation criteria in solid tumors)) was calculated and where appropriate functional liver remnant (FLR) is presented. Mean FLR increase was 264cm3 (range − 123 to 909), and all cases demonstrated a partial response according to RECIST with a mean largest lesion volume reduction of 475cm3 (range 14–1632). No post-SIRT complications were noted. Hepatectomy occurred at a mean of 322 days from SIRT treatment. Ninety-day morbidity was 67% (n = 6), complications post-surgery were analyzed according to the Clavien-Dindo classification scale; a total of 15 events occurred in 6 patients. Ninety-day mortality of 11% (n = 1).ConclusionIn selected cases, liver resection is possible post SIRT. As this can represent a potentially curative option, it is important to reconsider resection in the follow-up of patients undergoing SIRT. Post-operative complications are noted following major and extended liver resection. Therefore, further studies are needed to improve patient selection.

Highlights

  • Selective internal radiotherapy (SIRT) with yttrium-90 (Y-90) is an intra-arterial therapy for hepatic malignancy in patients who are unsuitable for surgical resection

  • Most of the reported clinical evidence for SIRT is in the context of metastatic colorectal cancer, hepatocellular carcinoma (HCC), and metastatic neuroendocrine tumors [2]

  • In HCC, SIRT may improve survival when compared with transarterial chemoembolization (TACE) and have potentially similar overall survival compared with sorafenib, but with an improved side effect profile [8, 9]

Read more

Summary

Introduction

Selective internal radiotherapy (SIRT) with yttrium-90 (Y-90) is an intra-arterial therapy for hepatic malignancy in patients who are unsuitable for surgical resection. This treatment is considered palliative, some patients can demonstrate a response that is adequate to facilitate surgical resection with curative intent. Selective internal radiotherapy (SIRT) with yttrium-90 (Y90) is an intra-arterial directed therapy for hepatic malignancy. For mCRC, data demonstrates SIRT can improve progression-free survival in the liver, results on its influence on overall survival and quality of life are evolving [4,5,6,7]. For mNET, SIRT has been associated with a high response rate and improved survival [10]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call